Loading...
XNASAMRN
Market cap182mUSD
Dec 23, Last price  
0.44USD
1D
-3.57%
1Q
-23.94%
Jan 2017
-85.60%
Name

Amarin Corporation PLC

Chart & Performance

D1W1MN
XNAS:AMRN chart
P/E
—
P/S
0.59
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.52%
Rev. gr., 5y
6.01%
Revenues
307m
-16.87%
1,017,000500,000500,0007,365,0000000026,351,00054,202,00081,756,000130,084,000181,104,000229,214,000429,755,000614,060,000583,187,000369,193,000306,911,000
Net income
-59m
L-44.13%
4,012,000-18,707,000-26,920,000-38,197,000-20,021,000-59,317,000-249,589,000-69,126,000-179,184,000-166,227,000-56,364,000-115,204,000-86,350,000-67,865,000-116,445,000-22,645,000-18,000,0007,729,000-105,803,000-59,112,000
CFO
7m
P
-10,727,000-17,306,000-22,909,000-26,279,000-26,392,000-28,112,000-33,870,000-39,439,000-122,303,000-190,336,000-72,309,000-84,748,000-71,815,000-32,837,000-94,703,000-9,366,000-21,746,000-66,537,000-180,092,0006,880,000
Earnings
Apr 18, 2025

Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
URL
https://amarincorp.com/
IPO date
Apr 01, 1993
Employees
365
Domiciled in
IE
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
306,911
-16.87%
369,193
-36.69%
583,187
-5.03%
Cost of revenue
363,527
461,536
558,968
Unusual Expense (Income)
NOPBT
(56,616)
(92,343)
24,219
NOPBT Margin
4.15%
Operating Taxes
5,442
1,998
3,562
Tax Rate
14.71%
NOPAT
(62,058)
(94,341)
20,657
Net income
(59,112)
-44.13%
(105,803)
-1,468.91%
7,729
-142.94%
Dividends
Dividend yield
Proceeds from repurchase of equity
239
(379)
(5,074)
BB yield
-0.07%
0.08%
0.37%
Debt
Debt current
10,034
207,509
Long-term debt
17,474
20,030
17,152
Deferred revenue
2,509
13,147
14,060
Other long-term liabilities
9,064
8,205
7,648
Net debt
(303,185)
(280,572)
(264,463)
Cash flow
Cash from operating activities
6,880
(180,092)
(66,537)
CAPEX
(599)
Cash from investing activities
(25,522)
175,288
104,103
Cash from financing activities
230
(379)
(5,073)
FCF
(75,810)
32,535
931
Balance
Cash
320,659
309,361
454,128
Long term investments
1,275
34,996
Excess cash
305,313
292,176
459,965
Stockholders' equity
(1,283,607)
(1,228,249)
(1,127,421)
Invested Capital
1,856,014
1,864,983
2,032,313
ROIC
1.03%
ROCE
2.68%
EV
Common stock shares outstanding
407,655
401,155
402,480
Price
0.87
-28.10%
1.21
-64.09%
3.37
-31.08%
Market cap
354,660
-26.93%
485,398
-64.21%
1,356,358
-27.34%
EV
51,475
204,826
1,091,895
EBITDA
(53,651)
(89,247)
27,076
EV/EBITDA
40.33
Interest
8
15
129
Interest/NOPBT
0.53%